3.76 USD
+0.08 (+2.17%)
3.7 USD
-0.06 (-1.6%)
Taking everything into account, MRVI scores 2 out of 10 in our fundamental rating. MRVI was compared to 58 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
MRVI had negative earnings in the past year.
In the past year MRVI has reported a negative cash flow from operations.
In multiple years MRVI reported negative net income over the last 5 years.
MRVI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MRVI has a Return On Assets of -14.28%. This is comparable to the rest of the industry: MRVI outperforms 41.38% of its industry peers.
MRVI's Return On Equity of -49.40% is on the low side compared to the rest of the industry. MRVI is outperformed by 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.28% | ||
| ROE | -49.4% | ||
| ROIC | N/A |
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 20.86%, MRVI is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of MRVI has declined.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
2. Health
2.1 Basic Checks
MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRVI has been increased compared to 1 year ago.
The number of shares outstanding for MRVI has been reduced compared to 5 years ago.
The debt/assets ratio for MRVI has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.10, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
MRVI has a worse Altman-Z score (1.10) than 63.79% of its industry peers.
A Debt/Equity ratio of 1.29 is on the high side and indicates that MRVI has dependencies on debt financing.
With a Debt to Equity ratio value of 1.29, MRVI is not doing good in the industry: 81.03% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.1 |
ROIC/WACCN/A
WACC11.27%
2.3 Liquidity
MRVI has a Current Ratio of 5.29. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MRVI (5.29) is better than 81.03% of its industry peers.
A Quick Ratio of 4.56 indicates that MRVI has no problem at all paying its short term obligations.
MRVI has a better Quick ratio (4.56) than 81.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.29 | ||
| Quick Ratio | 4.56 |
3. Growth
3.1 Past
The earnings per share for MRVI have decreased strongly by -900.00% in the last year.
Looking at the last year, MRVI shows a very negative growth in Revenue. The Revenue has decreased by -30.56% in the last year.
MRVI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.61% yearly.
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-30.56%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-36.15%
3.2 Future
MRVI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.92% yearly.
MRVI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.10% yearly.
EPS Next Y-220.75%
EPS Next 2Y-45.21%
EPS Next 3Y-5.34%
EPS Next 5Y-12.92%
Revenue Next Year-26.2%
Revenue Next 2Y-11.02%
Revenue Next 3Y-4.63%
Revenue Next 5Y-1.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MRVI's earnings are expected to decrease with -5.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.21%
EPS Next 3Y-5.34%
5. Dividend
5.1 Amount
MRVI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.76
+0.08 (+2.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners76.4%
Inst Owner Change3%
Ins Owners5.33%
Ins Owner Change39.68%
Market Cap961.47M
Revenue(TTM)192.28M
Net Income(TTM)-121.24M
Analysts76.47
Price Target3.93 (4.52%)
Short Float %11.95%
Short Ratio8.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.34%
Min EPS beat(2)-10.61%
Max EPS beat(2)3.93%
EPS beat(4)1
Avg EPS beat(4)-15.88%
Min EPS beat(4)-47.06%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-14.07%
EPS beat(12)4
Avg EPS beat(12)-40.43%
EPS beat(16)8
Avg EPS beat(16)-26.46%
Revenue beat(2)0
Avg Revenue beat(2)-9.3%
Min Revenue beat(2)-16.71%
Max Revenue beat(2)-1.9%
Revenue beat(4)1
Avg Revenue beat(4)-4.39%
Min Revenue beat(4)-16.71%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.71%
Revenue beat(12)4
Avg Revenue beat(12)-2.4%
Revenue beat(16)7
Avg Revenue beat(16)-1.24%
PT rev (1m)-3.57%
PT rev (3m)-35.36%
EPS NQ rev (1m)2.72%
EPS NQ rev (3m)0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.69%
Revenue NQ rev (1m)0.8%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.75
BVpS0.96
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.28% | ||
| ROE | -49.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.86% | ||
| FCFM | N/A |
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score5
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.54% | ||
| Cap/Sales | 9.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.29 | ||
| Quick Ratio | 4.56 | ||
| Altman-Z | 1.1 |
F-Score5
WACC11.27%
ROIC/WACCN/A
Cap/Depr(3y)93.62%
Cap/Depr(5y)87.93%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-220.75%
EPS Next 2Y-45.21%
EPS Next 3Y-5.34%
EPS Next 5Y-12.92%
Revenue 1Y (TTM)-30.56%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-36.15%
Revenue Next Year-26.2%
Revenue Next 2Y-11.02%
Revenue Next 3Y-4.63%
Revenue Next 5Y-1.1%
EBIT growth 1Y-193.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1991.95%
EBIT Next 3Y183.62%
EBIT Next 5Y97.71%
FCF growth 1Y-141.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.7%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%
MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ
What is the ChartMill fundamental rating of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MRVI.
What is the valuation status of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
ChartMill assigns a valuation rating of 0 / 10 to MARAVAI LIFESCIENCES HLDGS-A (MRVI). This can be considered as Overvalued.
Can you provide the profitability details for MARAVAI LIFESCIENCES HLDGS-A?
MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a profitability rating of 1 / 10.
What is the earnings growth outlook for MARAVAI LIFESCIENCES HLDGS-A?
The Earnings per Share (EPS) of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is expected to decline by -220.75% in the next year.